Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: H. Michael Petrassi Clear advanced filters

  • A preclinical covalent compound, CMX410, contains a aryl fluorosulfate warhead that targets the acyltransferase domain of Mtb Pks13, an essential enzyme in cell-wall biosynthesis, making it a promising candidate for tuberculosis treatment regimens.

    • Inna V. Krieger
    • Paridhi Sukheja
    • Case W. McNamara
    Research
    Nature
    Volume: 645, P: 755-763

  • The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in tuberculosis drug discovery by breaking down barriers among competing labs and institutions, has reached a 10-year landmark. We review the consortium’s achievements, advantages and limitations and advocate for the application of similar models to other diseases.

    • Bree B. Aldridge
    • David Barros-Aguirre
    • Ying Yuan
    Comments & Opinion
    Nature Medicine
    Volume: 27, P: 1333-1337

  • High-throughput chemical screening identified several groups of compounds that selectively block superoxide production from the outer Q-binding site of mitochondrial complex III and protect against ROS-induced oxidative stress in pancreatic β cells.

    • Adam L Orr
    • Leonardo Vargas
    • Martin D Brand
    Research
    Nature Chemical Biology
    Volume: 11, P: 834-836